Get the Stockscreener App
16.52
3.17%
-0.54
Xencor Inc stock is traded at $16.52, with a volume of 498.83K.
It is down -3.17% in the last 24 hours and up +14.80% over the past month.
Xencor Inc a clinical-stage biopharmaceutical company focused on discovering and developing engineered antibody therapeutics to treat patients with cancer and autoimmune diseases. The company uses its XmAb technology platform to create antibody product candidates. Its pipeline includes XmAb819, XmAb541, XmAb808, XmAb942, Plamotamab, and XmAb657. The group earns its revenue from collaboration agreements, product licensing agreements, and technology licensing agreements.
See More
Previous Close:
$17.06
Open:
$17.02
24h Volume:
498.83K
Relative Volume:
0.44
Market Cap:
$1.18B
Revenue:
$133.62M
Net Income/Loss:
$-177.37M
P/E Ratio:
-5.7163
EPS:
-2.89
Net Cash Flow:
$23.50M
1W Performance:
-4.51%
1M Performance:
+14.80%
6M Performance:
+75.19%
1Y Performance:
-33.28%
1-Day Range:
$16.43
$17.14
1-Week Range:
$16.43
$18.30
52-Week Range:
$6.92
$25.54
Xencor Inc Stock (XNCR) Company Profile
Name
Xencor Inc
Sector
Industry
Phone
626-305-5900
Address
465 N. HALSTEAD ST., PASADENA, CA
Compare XNCR with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
XNCR
Xencor Inc
|
16.52 | 1.22B | 133.62M | -177.37M | 23.50M | -2.89 |
|
VRTX
Vertex Pharmaceuticals Inc
|
452.04 | 113.14B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
741.29 | 78.49B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ARGX
Argen X Se Adr
|
877.94 | 54.76B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
397.55 | 54.51B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
INSM
Insmed Inc
|
197.01 | 41.64B | 447.02M | -1.18B | -906.14M | -6.1812 |
Xencor Inc Stock (XNCR) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-24-25 | Initiated | Truist | Buy |
| Oct-29-25 | Upgrade | Barclays | Underweight → Overweight |
| Sep-17-25 | Resumed | Barclays | Underweight |
| Sep-03-25 | Downgrade | BofA Securities | Buy → Neutral |
| Apr-21-25 | Initiated | William Blair | Outperform |
| Dec-12-24 | Initiated | Wells Fargo | Overweight |
| Dec-02-24 | Upgrade | Piper Sandler | Neutral → Overweight |
| Apr-16-24 | Reiterated | BTIG Research | Buy |
| Feb-28-24 | Downgrade | Piper Sandler | Overweight → Neutral |
| May-19-23 | Initiated | BofA Securities | Buy |
| Dec-06-22 | Initiated | Cowen | Outperform |
| Oct-13-22 | Upgrade | Raymond James | Outperform → Strong Buy |
| Sep-21-22 | Initiated | JP Morgan | Overweight |
| Jul-06-22 | Resumed | Canaccord Genuity | Buy |
| Feb-11-22 | Initiated | BMO Capital Markets | Outperform |
| Jan-21-22 | Initiated | SMBC Nikko | Outperform |
| Dec-15-21 | Initiated | H.C. Wainwright | Buy |
| Oct-15-21 | Resumed | BTIG Research | Buy |
| Feb-24-21 | Upgrade | Raymond James | Mkt Perform → Outperform |
| Mar-04-20 | Initiated | Barclays | Underweight |
| Feb-25-20 | Upgrade | Guggenheim | Neutral → Buy |
| Jan-30-20 | Initiated | RBC Capital Mkts | Outperform |
| Nov-20-19 | Resumed | Guggenheim | Neutral |
| Aug-07-19 | Downgrade | Guggenheim | Buy → Neutral |
| Aug-07-19 | Downgrade | Raymond James | Outperform → Mkt Perform |
| Jun-13-19 | Initiated | Mizuho | Buy |
| Apr-12-19 | Initiated | Guggenheim | Buy |
| Mar-27-19 | Initiated | Berenberg | Buy |
| Mar-15-19 | Initiated | Raymond James | Outperform |
| Sep-10-18 | Resumed | BTIG Research | Buy |
| Mar-28-18 | Resumed | Leerink Partners | Outperform |
| Mar-02-17 | Initiated | Instinet | Neutral |
| Mar-02-17 | Reiterated | Wedbush | Outperform |
| Oct-04-16 | Initiated | Piper Jaffray | Overweight |
| Dec-22-15 | Initiated | Canaccord Genuity | Buy |
| Aug-05-15 | Reiterated | MLV & Co | Buy |
| Feb-12-15 | Reiterated | Oppenheimer | Outperform |
| Jan-28-15 | Reiterated | MLV & Co | Buy |
| Jul-11-14 | Initiated | Oppenheimer | Outperform |
View All
Xencor Inc Stock (XNCR) Latest News
Fundamentals Check: Why Xencor Inc XE9 stock signals breakout potential - moha.gov.vn
Xencor Announces Extension of U.S. Patent Term on Certain Xtend™ Antibodies - BioSpace
Xencor (XNCR) Is Up 7.1% After Ultomiris Royalty Patent ExtensionWhat's Changed - simplywall.st
248,706 Shares in Xencor, Inc. $XNCR Acquired by Walleye Capital LLC - MarketBeat
Xencor Granted US Patent Extension of Certain Xtend Antibodies, Expects Additional Royalty Revenue - marketscreener.com
Xencor issued U.S. patent for Xtend Fc domain - TipRanks
Xencor extends Ultomiris royalty term to 2028 with new patent - Investing.com
Xencor extends Ultomiris royalty term to 2028 with new patent By Investing.com - Investing.com South Africa
Xencor Stock Jump Looks Great, But How Secure Is That Gain? - Trefis
Pullback Watch: What momentum indicators show for Xencor Inc stock2025 Sector Review & Smart Swing Trading Alerts - moha.gov.vn
Is Xencor Stock Built to Withstand a Pullback? - Trefis
How Xencor Inc. stock performs in interest rate cycles2025 Geopolitical Influence & Detailed Earnings Play Alerts - Newser
Xencor, Inc. $XNCR Shares Acquired by Panagora Asset Management Inc. - MarketBeat
What hedge fund moves indicate for Xencor Inc. (XE9) stockWeekly Earnings Recap & Low Drawdown Investment Strategies - Newser
What momentum indicators show for Xencor Inc. stock2025 Price Action Summary & High Conviction Investment Ideas - Newser
Its Stock Has Paid Off Big Time For Xencor Inc - setenews.com
Is Xencor Inc. stock a defensive play in 2025Quarterly Profit Review & Daily Growth Stock Investment Tips - Newser
Xencor (XNCR) Stock Analysis Report | Ratings, Financials & Performance - Benzinga
Xencor Inc. diskutieren - sharewise.com
How supply shortages influence Xencor Inc. (XE9) stockJuly 2025 Opening Moves & Safe Capital Investment Plans - BỘ NỘI VỤ
Xencor, Inc. (XNCR) Stock Forecasts - Yahoo Finance
Xencor, Inc. (NASDAQ:XNCR) Given Consensus Recommendation of "Moderate Buy" by Analysts - MarketBeat
Rhenman & Partners Asset Management AB Has $1.30 Million Stake in Xencor, Inc. $XNCR - MarketBeat
Will Xencor Inc. (XE9) stock remain on Wall Street radarJuly 2025 Sector Moves & Real-Time Volume Triggers - BỘ NỘI VỤ
Truist Financial Initiates a Buy Rating on Xencor (XNCR) - The Globe and Mail
Xencor (NASDAQ:XNCR) Coverage Initiated by Analysts at Truist Financial - MarketBeat
There's No Escaping Xencor, Inc.'s (NASDAQ:XNCR) Muted Revenues Despite A 27% Share Price Rise - simplywall.st
DCF Advisers LLC Cuts Stake in Xencor, Inc. $XNCR - MarketBeat
Xencor Shares Surge on Clinical Breakthroughs and Analyst Confidence - Ad-hoc-news.de
Truist Securities Initiates Coverage of Xencor (XNCR) with Buy Recommendation - MSN
Truist Securities initiates coverage on Xencor stock with Buy rating By Investing.com - Investing.com Canada
Truist Securities Initiates Coverage on Xencor (XNCR) with Buy R - GuruFocus
Truist Securities initiates coverage on Xencor stock with Buy rating - Investing.com India
Xencor’s XmAb819 Study: A Promising Step in Cancer Treatment - MSN
Primecap Management Co. CA Has $82.75 Million Holdings in Xencor, Inc. $XNCR - MarketBeat
Is Xencor Inc. stock a safe buy before earningsJuly 2025 Reactions & Free High Accuracy Swing Entry Alerts - newser.com
Will Xencor Inc. (XE9) stock benefit from commodity supercycleJuly 2025 Outlook & Weekly Setup with High ROI Potential - newser.com
Xencor Shares Show Renewed Promise as Biotech Specialist Stages Recovery - Ad-hoc-news.de
Bank of Montreal Can Boosts Holdings in Xencor, Inc. $XNCR - MarketBeat
Xencor Inc (XE9.MU) Stock Price, News, Quote & History - Yahoo! Finance Canada
Is Xencor Inc. (XE9) stock undervalued by metricsWeekly Loss Report & Free Long-Term Investment Growth Plans - newser.com
Xencor upgraded to Overweight from Underweight at Barclays - MSN
Will Xencor Inc. (XE9) stock hit Wall Street targetsWatch List & Long Hold Capital Preservation Plans - newser.com
Xencor Inc Stock (XNCR) Financials Data
Revenue
Net Income
Cash Flow
EPS
1.08%
0.91%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):